PL354920A1 - Zastosowanie apomorfiny w wytwarzaniu leku przeznaczonego do leczenia organicznych zaburzesigma erekcji u mężczyzn - Google Patents

Zastosowanie apomorfiny w wytwarzaniu leku przeznaczonego do leczenia organicznych zaburzesigma erekcji u mężczyzn

Info

Publication number
PL354920A1
PL354920A1 PL99354920A PL35492099A PL354920A1 PL 354920 A1 PL354920 A1 PL 354920A1 PL 99354920 A PL99354920 A PL 99354920A PL 35492099 A PL35492099 A PL 35492099A PL 354920 A1 PL354920 A1 PL 354920A1
Authority
PL
Poland
Prior art keywords
apomorphine
males
medicament
manufacture
treatment
Prior art date
Application number
PL99354920A
Other languages
English (en)
Inventor
Karen Kling
Renee J. Perdok
Dustin D. Ruff
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of PL354920A1 publication Critical patent/PL354920A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
PL99354920A 1998-12-17 1999-12-13 Zastosowanie apomorfiny w wytwarzaniu leku przeznaczonego do leczenia organicznych zaburzesigma erekcji u mężczyzn PL354920A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/213,567 US6291471B1 (en) 1998-12-17 1998-12-17 Use of apomorphine for the treatment of organic erectile dysfunction in males

Publications (1)

Publication Number Publication Date
PL354920A1 true PL354920A1 (pl) 2004-03-22

Family

ID=22795606

Family Applications (1)

Application Number Title Priority Date Filing Date
PL99354920A PL354920A1 (pl) 1998-12-17 1999-12-13 Zastosowanie apomorfiny w wytwarzaniu leku przeznaczonego do leczenia organicznych zaburzesigma erekcji u mężczyzn

Country Status (22)

Country Link
US (1) US6291471B1 (pl)
EP (1) EP1140094A1 (pl)
JP (1) JP2003521462A (pl)
KR (1) KR20010101241A (pl)
CN (1) CN1335772A (pl)
AR (1) AR021912A1 (pl)
AU (1) AU2175800A (pl)
BG (1) BG105664A (pl)
BR (1) BR9916114A (pl)
CA (1) CA2354601A1 (pl)
CZ (1) CZ20012084A3 (pl)
HK (1) HK1043303A1 (pl)
HU (1) HUP0201618A3 (pl)
IL (1) IL143410A0 (pl)
NO (1) NO20012985L (pl)
NZ (1) NZ511790A (pl)
PL (1) PL354920A1 (pl)
SK (1) SK8262001A3 (pl)
TR (1) TR200101719T2 (pl)
TW (1) TW577740B (pl)
WO (1) WO2000035457A1 (pl)
ZA (1) ZA200104146B (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566368B2 (en) * 1994-04-22 2003-05-20 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage form for ameliorating male erectile dysfunction
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
WO2002041894A2 (en) * 2000-11-22 2002-05-30 Abbott Laboratories Selective dopamine d4 receptor agonists for treating sexual dysfunction
AR032556A1 (es) * 2001-02-08 2003-11-12 Pharmacia Corp Medicamento de accion inmediata para el tratamiento de la disfuncion sexual
JP2005526790A (ja) * 2002-03-19 2005-09-08 ミシェル ホリック アポモルフィンおよび類縁体の配糖体およびオルトエステル配糖体誘導体、ならびにそれらの使用方法
SE0202365D0 (sv) 2002-08-05 2002-08-05 Pharmacia Ab New formulation and use thereof
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
CA2522231A1 (en) * 2003-04-14 2004-10-21 Vectura Ltd Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
US7648995B2 (en) * 2004-04-13 2010-01-19 The Mclean Hospital Corporation R(—)-11-hydroxyaporphine derivatives and uses thereof
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
US8431591B2 (en) * 2007-07-12 2013-04-30 The Mclean Hospital Corporation R(−)-2-methoxy-11-hydroxyaporphine and derivatives thereof
BRPI0800596A2 (pt) 2008-01-31 2009-09-22 Univ Minas Gerais método para a potencialização da função erétil através do uso das composições farmacêuticas de toxina tx2-6 da aranha phoneutria nigriventer
PT2651357T (pt) 2010-12-16 2020-06-17 Sunovion Pharmaceuticals Inc Películas sublinguais
KR101374500B1 (ko) * 2012-10-09 2014-03-13 울산대학교 산학협력단 Ｒ(-)-프로필노르아포모르핀을 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
PT2981271T (pt) 2013-04-05 2019-02-19 Boehringer Ingelheim Int Utilizações terapêuticas de empagliflozina
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2909728C (en) 2013-04-18 2022-12-06 Boehringer Ingelheim International Gmbh Therapeutic uses of empagliflozin
WO2016174155A1 (en) * 2015-04-30 2016-11-03 Boehringer Ingelheim International Gmbh Methods and pharmaceutical compositions comprising a sglt2 inhibitor for treating or improving erectile dysfunction
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
WO2019241585A1 (en) * 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for treating erectile dysfunction with a cgmp-specific phosphodiesterase 5 inhibitor pharmaceutical composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256652A (en) 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
US5270323A (en) 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
US5292520A (en) 1990-09-13 1994-03-08 Akzo N.V. Stabilized solid pharmaceutical composition containing acid addition salts of a basic drug and an alkaline stabilizer
DK0689438T3 (da) 1993-03-26 2003-09-29 Franciscus Wilhelmus He Merkus Farmaceutiske præparater til intranasal administration af apomorfin
DK0978282T3 (da) * 1994-04-22 2006-04-10 Pentech Pharmaceuticals Inc Sublingualt præparat indeholdende apomorphin til diagnosticering af funktionel impotens
US5562917A (en) 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5688499A (en) 1996-03-13 1997-11-18 Queen's University At Kingston Antagonism of endothelin actions
DE19652268C2 (de) 1996-12-16 2000-06-29 Lohmann Therapie Syst Lts Arzneizubereitung für die Freisetzung von Apomorphin in der Mundhöhle

Also Published As

Publication number Publication date
TR200101719T2 (tr) 2002-08-21
EP1140094A1 (en) 2001-10-10
NZ511790A (en) 2004-04-30
NO20012985L (no) 2001-08-16
SK8262001A3 (en) 2002-01-07
BG105664A (en) 2002-02-28
WO2000035457A1 (en) 2000-06-22
BR9916114A (pt) 2003-01-14
HUP0201618A2 (en) 2002-09-28
CZ20012084A3 (cs) 2002-01-16
JP2003521462A (ja) 2003-07-15
TW577740B (en) 2004-03-01
AR021912A1 (es) 2002-09-04
CN1335772A (zh) 2002-02-13
HUP0201618A3 (en) 2003-03-28
ZA200104146B (en) 2002-08-21
CA2354601A1 (en) 2000-06-22
HK1043303A1 (zh) 2002-09-13
IL143410A0 (en) 2002-04-21
AU2175800A (en) 2000-07-03
KR20010101241A (ko) 2001-11-14
US6291471B1 (en) 2001-09-18
NO20012985D0 (no) 2001-06-15

Similar Documents

Publication Publication Date Title
HUP0201618A2 (en) Use of apomorphine in the manufacture of a medicament for the treatment of organic erectile dysfunction in males
FI972205A0 (fi) cGmp-PDE:n estäjiä erektiohäiriön hoidossa
IL196301A0 (en) Medicament for the treatment of hapatitis c
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
HUP0204333A3 (en) Use of csaids in rhinovirus infection
HUP0301828A3 (en) Use of apomorphine for the production of pharmaceutical compositions for treating sexual dysfunction with apomorphine at specified plasma concentration levels
AU2001274649A1 (en) Topical preparation of alprostadil for the treatment of erectile dysfunction
HK1037517A1 (en) Use of apomorphine in the treatment of premature ejaculation
GB9816234D0 (en) Compounds for use in the treatment of inflammation
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
AU6605800A (en) Melanocortin receptor-3 ligands to treat sexual dysfunction
IL162154A0 (en) Prostagandin composition for the treatment of erectile dysfunction
HUP0300339A3 (en) Use of fulvestrant in the treatment of resistant breast cancer
EP1079764A4 (en) TREATMENT OF SEXUALITY DISORDERS IN CERTAIN GROUPS OF PATIENTS
AU4676099A (en) Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
AU7652400A (en) Novel combination for the treatment of sexual dysfunction
IL154215A0 (en) Medicine for fighting against sexual dysfunction
GB9917346D0 (en) Medicament for treating premature ejaculation
PL362980A1 (pl) Sposób leczenia dysfunkcji seksualnej
GB9904252D0 (en) Composition for the treatment of pain
EE200200348A (et) Ravimkoostis kasutamiseks valu ravis
SI1173178T1 (sl) Sestavek, ki obsega apomorfin in seldenafil, in njegova uporaba za zdravljenje erektilne disfunkcije
SI1047428T1 (sl) Uporaba morfolinola za zdravljenje seksualne disfunkcije
ZA991676B (en) A device for use in the treatment of erectile dysfunction.
AU2984399A (en) Pge-1 containing lyopholized liposomes for use in the treatment of erectile dysfunction

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)